Infliximab Infusion Rates in Pediatric Inflammatory Bowel Disease

Launched by UNIVERSITY HOSPITAL, AKERSHUS · Feb 17, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how quickly infliximab, a medication used to treat Inflammatory Bowel Disease (IBD) in children and teenagers, can be safely administered. The study aims to find out if giving this medicine in 30 minutes instead of the usual 60 minutes leads to fewer side effects during the infusion. It will also look at how satisfied both patients and nurses are with these different infusion times and how it affects the overall time spent in the hospital.

To participate in this trial, children aged 0 to 17 who have IBD and have already received at least five infliximab infusions are eligible. Participants can expect to receive their medication in either 30 or 60 minutes while being monitored for any reactions and their overall experience. This study is currently recruiting participants and aims to help improve the care and comfort of young patients receiving treatment for IBD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pediatric IBD patients on infliximab
• • 1-17 years
• • Received at least 5 infusions of infliximab prior to entry in the study
• Exclusion Criteria:
• • Receiving infliximab for non-IBD condition (reumatological or other causes)
• • previous severe infliximab infusion reaction
• • need for an interpreter
• • heart failure with hemodynamic impact
• • unwillingness to participate